Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

Summary

This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.

Timeline

Start

2021-07-23

Primary completion

2023-01-31

Completion

2023-01-31

Drugs

Indications